TBVAC-HORIZON consortium

The TBVAC-HORIZON consortium consists of 19 partners and builds upon over two decades of collaborative R&D and has been the major contributor to the current global TB vaccine pipeline.

Consortium partners:

  • TuBerculosis Vaccine Initiative (TBVI) (Coordinator)
  • Biomedical Primate Research Centre (BPRC)
  • Centre National de la Recherche Scientifique (CNRS)
  • Universit√© Toulouse III – Paul Sabatier (UT3)
  • Istituto Nazionale per le Malattie Infettive ‘Lazzaro Spallanzani’ (INMI-IRCCS)
  • Institut Pasteur (IP)
  • Institut Pasteur de Lille (IPL)
  • Leiden University Medical Centre (LUMC)
  • Statens Serum Institut (SSI)
  • University of Zaragoza (UNIZAR)
  • University of Ulm (UULM)
  • CZ Vaccines, S.A. (CZV)
  • University of Basel (UNIBAS)
  • Vaccine Formulation Institute CH, Ltd. (VFI)
  • Department of Health (UKHSA)
  • London School of Hygiene and Tropical Medicine (LSHTM)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • University of Leicester (ULEIC)
  • University of Oxford (UOXF)